Skip to main content

Vor Bio to Participate in the JMP Securities Hematology and Oncology Summit

CAMBRIDGE, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host virtual 1x1 investor meetings at the JMP Securities Hematology and Oncology Summit.

JMP Securities Hematology and Oncology Summit
Fireside Chat: Tuesday, December 5, 2023 at 1:30 pm ET
Location: Virtual

About Vor Bio
Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.

Contact:

Media & Investors
Sarah Spencer
+1 857-242-6076
sspencer@vorbio.com


Primary Logo

Recent Quotes

View More
Symbol Price Change (%)
AMZN  212.37
+2.60 (1.24%)
AAPL  259.13
+3.21 (1.25%)
AMD  220.21
+2.71 (1.25%)
BAC  49.83
+0.45 (0.91%)
GOOG  295.71
+1.25 (0.42%)
META  577.97
+3.51 (0.61%)
MSFT  371.36
-2.10 (-0.56%)
NVDA  177.00
-0.39 (-0.22%)
ORCL  144.33
-2.05 (-1.40%)
TSLA  352.78
-7.81 (-2.17%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.